Report Id: PEGFRIM0120
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size By Type (Lung Cancer, Colorectal Cancer, Breast Cancer), By Application (Hospital, Research Institutes and Institutions, Clinic, Other), By Region (North America, Europe, Asia-Pacific, Rest of the World), Market Analysis Report, Forecast 2023-2028
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market will grow by US$ 3.15 Billion by 2028 at a CAGR of 9.2% in the given forecast period.
COVID-19 Impact Analysis Report
"Get Latest Updated Reports as per the COVID-19 Impact"
Infopedia: Access Our All Reports Online at Affordable Price
CLICK HEREMARKET SNAPSHOT
Major Players
- Amgen Inc.
- AstraZeneca Plc
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd
- Novartis AG
Study period:
Fastest Growing Market:
2023-2028
APAC
Base Year:
Largest Market:
2022
North America
CAGR:
9
REPORT DESCRIPTION
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market will grow by US$ 3.15 Billion by 2028 at a CAGR of 9.2% in the given forecast period.
The epidermal growth factor receptor (EGFR) is a protein-coding gene. It is found in high levels on cancer cells and is known to be responsible for the uncontrolled cell growth Inhibiting or blocking the growth of EGFR can stop the growth of cancer cells for long durations of time.
This rising occurrence of cancer can be attributed to factors such as increasing geriatric population and changing lifestyle. The increasing special drug designations and the high efficacy of EGFR inhibitors in the treatment of cancer indications such as lung cancer, colorectal cancer, and breast cancer will result in quicker approval during the clinical stages. Thus, the strong prevalence of major cancer indications will be a significant factor driving epidermal growth factor receptor inhibitors market.
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market is segregated on the basis of Type as Lung Cancer, Colorectal Cancer, Breast Cancer, and Others. Based on Application the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market is segmented in Hospital, Research Institutes and Institutions, Clinic, and Other.
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Epidermal Growth Factor Receptor (EGFR) Inhibitor market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG, and others are among the major players in the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Market has been segmented as below:
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Application
- Hospital
- Research Institutes and Institutions
- Clinic
- Other
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Company
- Amgen Inc.
- AstraZeneca Plc
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
The report covers:
- Global Epidermal Growth Factor Receptor (EGFR) Inhibitor market sizes from 2022 to 2028, along with CAGR for 2023-2028
- Market size comparison for 2022 vs 2028, with actual data for 2022, estimates for 2023 and forecast from 2024 to 2028
- Global Epidermal Growth Factor Receptor (EGFR) Inhibitor market trends, covering comprehensive range of consumer trends & manufacturer trends
- Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market
- Major market opportunities and challenges in forecast timeframe to be focused
- Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
- Comprehensive company profiles of the key industry players
Report Scope:
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market share. Major industry players with significant revenue share include Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG, and others.
Reasons to Buy this Report:
- Gain detailed insights on the Epidermal Growth Factor Receptor (EGFR) Inhibitor industry trends
- Find complete analysis on the market status
- Identify the Epidermal Growth Factor Receptor (EGFR) Inhibitor market opportunities and growth segments
- Analyse competitive dynamics by evaluating business segments & product portfolios
- Facilitate strategy planning and industry dynamics to enhance decision making
Customization
Customized report as per the requirement can be offered with appropriate recommendations.
Below are our New Reports :-
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter's Five Force Analysis
5. Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Type
5.1 Introduction
5.2 Lung Cancer
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Colorectal Cancer
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Breast Cancer
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Others
5.5.1 Market Overview
5.5.2 Market Size and Forecast
6. Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Application
6.1 Introduction
6.2 Hospital
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Research Institutes and Institutions
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Clinic
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Other
6.5.1 Market Overview
6.5.2 Market Size and Forecast
7. Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.2.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
7.3 Europe
7.3.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.3.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
7.4 Asia-Pacific
7.4.1 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.4.2 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
7.5 Rest of the World
7.5.1 Rest of the World Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.5.2 Rest of the World Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Amgen Inc.
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 AstraZeneca Plc
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Eli Lilly and Co.
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 F. Hoffmann-La Roche Ltd.
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 Novartis AG
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Market has been segmented as below:
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Application
- Hospital
- Research Institutes and Institutions
- Clinic
- Other
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Company
- Amgen Inc.
- AstraZeneca Plc
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
Got a question? We've got answers. If you have some other questions, see our support center.
What is the predicted growth rate of Epidermal Growth Factor Receptor (EGFR) Inhibitor Market?
The market is expected to grow at a CAGR of 9% during the study period (2023-2028)
How big is the Epidermal Growth Factor Receptor (EGFR) Inhibitor Market value?
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market will grow by US$ 3.15 Billion by 2028
What is the segment’s covered for the Epidermal Growth Factor Receptor (EGFR) Inhibitor market?
The segment included in the Epidermal Growth Factor Receptor (EGFR) Inhibitor market is Application, Type, Company and region.
Who are the major key vendors in the Epidermal Growth Factor Receptor (EGFR) Inhibitor market?
Some key players operating in the Epidermal Growth Factor Receptor (EGFR) Inhibitor market include Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG
What are the different forms of the report available?
We can offer several formats of the market research reports including,
• PDF
• PPT
• Spreadsheet/ Workbook
© 2020 COPYRIGHT : MARKET RESEARCH ENGINE